​
Login / Signup
Siqi Zhang
ORCID
Publication Activity (10 Years)
Years Active: 2023-2024
Publications (10 Years): 4
Top Topics
Cross Sectional
Pi K Akt
Epidermal Growth Factor Receptor
Prostate Cancer
Top Venues
Journal of medicinal chemistry
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Yan Lv
,
Zixuan Yang
,
Yiming Chen
,
Xuepei Ma
,
Mengqi Guo
,
Chengwei Zhang
,
Xiaolin Jiang
,
Chengli Wang
,
Zhuoyue Li
,
Zhengfu Tai
,
Xiao Wang
,
Siqi Zhang
,
Shumin Ma
,
Chong Qin
A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS G12C Inhibitor.
Journal of medicinal chemistry
67 (4) (2024)
Yan Lv
,
Zixuan Yang
,
Yiming Chen
,
Xuepei Ma
,
Mengqi Guo
,
Chengwei Zhang
,
Xiaolin Jiang
,
Chengli Wang
,
Zhuoyue Li
,
Zhengfu Tai
,
Xiao Wang
,
Siqi Zhang
,
Shumin Ma
,
Chong Qin
A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS G12C Inhibitor.
Journal of medicinal chemistry
(2024)
Yan Lv
,
Zixuan Yang
,
Yiming Chen
,
Xuepei Ma
,
Mengqi Guo
,
Chengwei Zhang
,
Xiaolin Jiang
,
Chengli Wang
,
Zhuoyue Li
,
Zhengfu Tai
,
Xiao Wang
,
Siqi Zhang
,
Shumin Ma
,
Chong Qin
A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS G12C Inhibitor.
Journal of medicinal chemistry
67 (4) (2024)
Bowen Zhang
,
Chang Liu
,
Zhenqian Yang
,
Sai Zhang
,
Xiaolin Hu
,
Baohu Li
,
Mei Mao
,
Xiao Wang
,
Zhuoyue Li
,
Shumin Ma
,
Siqi Zhang
,
Chong Qin
Discovery of BWA-522 , a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer.
Journal of medicinal chemistry
(2023)